Drug Profile
CMB 305
Alternative Names: CMB-305; G-305/LV-305; ID-CMB305; ID-G305/ID-LV305; ID-LV305/ID-G305; LV-305/G-305Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Immune Design
- Developer Genentech; Immune Design
- Class Cancer vaccines; Immunotherapies; Peptide vaccines; Peptides; RNA vaccines; Synthetic vaccines
- Mechanism of Action Dendritic cell stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Sarcoma
Highest Development Phases
- Phase III Synovial sarcoma
- Phase II Soft tissue sarcoma
- No development reported Liposarcoma; Solid tumours
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for phase-I development in Liposarcoma(Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) in USA (Parenteral)
- 28 Oct 2021 No recent reports of development identified for phase-I development in Synovial-sarcoma(Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) in USA (Parenteral)
- 28 Aug 2020 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Locally recurrent, Metastatic disease, Monotherapy, In adults) in USA (Parenteral, Injection)